# Invus: portfolio, investments and team

> Invus is a private equity based in United States. 148 investments on record, 26 in the last 12 months, latest Oct 2026.

Source: https://millionrounds.com/fund/invus (Millionrounds; every figure on the page links to its filing or article)

United States · [Investor](https://millionrounds.com/investors)

# Invus

Last cheque observed Oct 2026; 148 cheques on record.

Email

Deploying now New fund, Mar 2025 Private equity

Growth Buyout AI & Machine Learning Artificial Intelligence & Machine Learning (AI/ML) Asia Private Equity

Follow Invus and see its new cheques in your feed. [Start following](https://millionrounds.com/login?join=1&why=follow&next=%2Ffund%2Finvus)

Deploying now

**90%** of best year **26** **cheques in 12 months**, 148 on record

Since the last cheque **24** days **00** hrs **00** min **00** sec

Median round **$81M** Rounds led **4 of 148** Sole investor **27 rounds** Exits **1 from the portfolio** Mostly in **United States, 78%**

Pitch Invus

## Invus highlights

- 01 26 cheques in the last 12 months
- 02 Mostly Venture and Series B: 55% of its rounds
- 03 Sole investor in 27 rounds, median $21M
- 04 1 exits from the portfolio

## What they do

> Includes investments in private companies where Invus was the only or the lead investor with $10M+ equity, and where the investment has been fully or partially exited since 1993. From their own website

- **Type:** Private equity
- **Cheque size:** From $10M as they say
- **Stages:** Growth Buyout
- **Sectors:** AI & Machine Learning Artificial Intelligence & Machine Learning (AI/ML) Asia Private Equity
- **Based in:** New York, United States
- **Cold pitches:** Not accepted

## The record

Every round we can evidence, newest first **148 appearances**

- **2026** 21 rounds
- **Oct** **[Matchpoint Therapeutics](https://millionrounds.com/company/matchpoint-therapeutics)** Series B · US · Firms' own news pages **$150M** With 9 others
- **Sept** **[EliseAI](https://millionrounds.com/company/eliseai)** Growth · US · TechCrunch **$350M** With 6 others
- **Sept** **[Precision Neuroscience](https://millionrounds.com/company/precision-neuroscience)** Growth · US · AlleyWatch **$250M** With 12 others
- **Sept** **[Caspian Therapeutics](https://millionrounds.com/company/caspian-therapeutics)** Series A · QRM Capital **$50M** With 7 others
- **Sept** **[Tyra Biosciences](https://millionrounds.com/company/tyra-biosciences)** US **$400M** With 5 others
- **Sept** **[One Biosciences](https://millionrounds.com/company/one-biosciences)** Grant · FR **$3.8M** With 3 others
- **Sept** **[Encoded Therapeutics](https://millionrounds.com/company/encoded-therapeutics)** Series F · US **$275M** With 4 others
- **Sept** **[Within](https://millionrounds.com/company/within)** Venture · US **$70M** With 4 others
- **Jul** **[Erasca](https://millionrounds.com/company/erasca)** US **$633M** With 4 others
- **Jul** **[BRIUS](https://millionrounds.com/company/brius)** Venture · US **$5.0M** With 2 others
- **Jun** **[City Therapeutics](https://millionrounds.com/company/city-therapeutics)** Series B · US · Ventureburn **$100M** With 8 others
- **Jun** **[Contraline](https://millionrounds.com/company/contraline)** Series B · Ventureburn **$93M** With 9 others
- **Jun** **[Osanni Bio](https://millionrounds.com/company/osanni-bio)** Series B · US **$190M** Sole investor
- **Jun** **[Engine Biosciences](https://millionrounds.com/company/engine-biosciences)** Venture · SG **Undisclosed** With 2 others
- **May** **[Cartesian Therapeutics](https://millionrounds.com/company/cartesian-therapeutics)** Debt · US **$50M** Sole investor
- **Apr** **[Ray Therapeutics](https://millionrounds.com/company/ray-therapeutics)** Series B · US · 4BIO Capital **$125M** With 10 others
- **Apr** **[VeraDermics](https://millionrounds.com/company/veradermics)** US **$384M** With 3 others
- **Mar** **[Solid Biosciences](https://millionrounds.com/company/solid-biosciences)** US · Firms' own news pages **$240M** With 8 others
- **Jan** **[Rapido](https://millionrounds.com/company/rapido)** Venture **Undisclosed** With 4 others
- **Jan** **[PrognomiQ](https://millionrounds.com/company/prognomiq)** Venture · US **$12M** With 4 others
- **Jan** **[Foghorn Therapeutics](https://millionrounds.com/company/foghorn-therapeutics)** US **$50M** With 3 others
- **2025** 18 rounds
- **Dec** **[Triana Biomedicines](https://millionrounds.com/company/triana-biomedicines)** Series B · US **$120M** With 3 others
- **Nov** **[MaaT Pharma](https://millionrounds.com/company/maat-pharma)** FR **$11M** With 3 others
- **Nov** **[Bambusa Therapeutics](https://millionrounds.com/company/bambusa-therapeutics)** Venture · US **Undisclosed** With 3 others
- **Nov** **[Aive](https://millionrounds.com/company/aive)** Series A · FR **$5.2M** With 4 others
- **Nov** **[Ablative Solutions](https://millionrounds.com/company/ablative-solutions)** Venture · US **$10M** Sole investor
- **Oct** **[Hemab](https://millionrounds.com/company/hemab)** Series C · DK **$157M** With 3 others
- **Oct** **[VeraDermics](https://millionrounds.com/company/veradermics)** Series C · US **$150M** With 2 others
- **Oct** **[Rani Therapeutics](https://millionrounds.com/company/rani-therapeutics)** US **$60M** With 3 others
- **Oct** **[LEXEO Therapeutics](https://millionrounds.com/company/lexeo-therapeutics)** US **$154M** With 4 others
- **Jul** **[Pretzel Therapeutics](https://millionrounds.com/company/pretzel-therapeutics)** Venture · US **Undisclosed** With 2 others
- **May** **[BRIUS](https://millionrounds.com/company/brius)** Series B · US **$20M** With 2 others
- **Apr** **[Rain](https://millionrounds.com/company/rain)** Series B · US · TechCrunch **$75M** With 9 others
- **Feb** **[ClearScore](https://millionrounds.com/company/clearscore)** Debt · GB **$38M** With 2 others
- **Feb** **[Bambusa Therapeutics](https://millionrounds.com/company/bambusa-therapeutics)** Series A · US **$90M** With 3 others
- **Feb** **[Dorsia](https://millionrounds.com/company/dorsia)** Series A · US **$50M** With 1 other
- **Jan** **[Coave Therapeutics](https://millionrounds.com/company/coave-therapeutics)** Series A · FR · Seroba Life Sciences **$33M** With 10 others
- **Jan** **[Leyden Labs](https://millionrounds.com/company/leyden-labs)** NL · Silicon Canals **$70M** With 9 others
- **Jan** **[Imvax](https://millionrounds.com/company/imvax)** Venture · US **$29M** Sole investor
- **2024** 17 rounds
- **Dec** **[Tasca](https://millionrounds.com/company/tasca)** Series A · US **$48M** With 1 other

An announcement gives the size of the round, not the size of this investor's cheque: the only rounds that imply a cheque are those where they were the sole named investor.

## The team

Named by the firm itself, on a filing, its Form ADV or its company registration **5 named**

BK **Bryan Kim** Vice President of the GP. i Filing they signed

CT **Carmen Taton** Chief Financial Officer i Form ADV

LL **Leslie Laura Lake** Vice President, Secretary, Treasurer i Form ADV

PJ **Philip Joseph Bafundo** Chief Compliance Officer i Form ADV

SL **Sacha Lainovic** Managing Member of the GP. i Filing they signed

We also hold **27** people at this firm from the lists this database was built from: a weaker source than the filings, since a list does not say when a title ended. Login to see them.

## What the register says

From the firm's own filings with the SEC, which it must file accurately by law

**$16B** assets it manages Oct 2026

**Registered** investment adviser full reporting to the SEC

- **Legal name:** Invus Financial Advisors, LLC
- **SEC number:** CRD 161603

Funds on its Form ADV

**23** private funds, **$5.8B** in gross assets · filed Nov 2024

Private equity **18** Hedge **4** Private investment vehicle **1**

- ATM, L.P. *Hedge* 1 investor $1.8B
- Invus, L.P. *Private investment vehicle* 2 investors $927M
- Invopps V, L.P. *Private equity* 24 investors $371M
- Invopps IV, L.P. *Private equity* 18 investors $370M
- Invus Opportunities Fund III, L.P. *Private equity* 4 investors $364M
- Invopps FT1A, LLC *Private equity* 38 investors $238M
- Invopps V US, L.P. *Private equity* 21 investors $236M
- Avicenna Life SCI Master Fund L.P. *Hedge* 4 investors $205M
- Invus Opportunities Fund III US, L.P. *Private equity* 14 investors $196M
- Invopps IV US, L.P. *Private equity* 18 investors $190M

And 13 more on the filing.

## Exits from the portfolio

Companies it backed that were later bought or listed **1 in all**

**[Netcontinuum](https://millionrounds.com/company/netcontinuum)** Bought by [Barracuda Networks](https://millionrounds.com/fund/barracuda-networks) **Undisclosed** Sept 2007

An exit counts when it came after the firm's first round in the company. From historical deal records.

New fund on file

**Raised**

a new fund in Mar 2025

From its SEC filing, not a journalist: a firm that has just raised has money to deploy.

## The cheque

Growth Buyout

Median round joined **$81M** the round, not its cheque Alone, median **$21M**

Led 4 of 148 rounds **3%**

- **Said size:** From $10M
- **Sole investor:** 27 rounds
- **Last cheque:** Oct 2026
- **Exits:** 1 from the portfolio

Rounds by stage said on their site

- Venture *30*
- Series B *29*
- Series A *27*
- Series C *14*
- Growth said *7*
- Buyout said *-*

Cheques by month Led Joined

Nov 2023 Oct 2026

Often in the room with

- [RA Capital Management](https://millionrounds.com/fund/ra-capital-management) 15
- [Fidelity](https://millionrounds.com/fund/fidelity) 11
- [Janus Henderson Investors](https://millionrounds.com/fund/janus-henderson-investors) 10
- [Casdin Capital](https://millionrounds.com/fund/casdin-capital) 9
- [OrbiMed](https://millionrounds.com/fund/orbimed) 9
- [Polaris Partners](https://millionrounds.com/fund/polaris-partners) 9

**Pitching Invus?** Put them on your fundraising board with this record on the card, and follow them to hear when they write a new cheque.

Add to your CRM *→*

## Who they invest alongside

The investors most often in the same rounds as Invus. A count of rooms they were both in, not a relationship either has claimed.

[**RA Capital Management** Private equity **15** rounds together](https://millionrounds.com/fund/ra-capital-management)[**Fidelity** VC firm **11** rounds together](https://millionrounds.com/fund/fidelity)[**Janus Henderson Investors** Private equity **10** rounds together](https://millionrounds.com/fund/janus-henderson-investors)[**Casdin Capital** VC firm **9** rounds together](https://millionrounds.com/fund/casdin-capital)[**OrbiMed** Private equity **9** rounds together](https://millionrounds.com/fund/orbimed)[**Polaris Partners** VC firm **9** rounds together](https://millionrounds.com/fund/polaris-partners)[**Google Ventures** Corporate VC **8** rounds together](https://millionrounds.com/fund/gv)[**Redmile Group** VC firm **8** rounds together](https://millionrounds.com/fund/redmile-group)[**ARCH Venture Partners** VC firm **7** rounds together](https://millionrounds.com/fund/arch-venture-partners)[**Flagship Pioneering** VC firm **7** rounds together](https://millionrounds.com/fund/flagship-pioneering)[**Novo Holdings** VC firm **7** rounds together](https://millionrounds.com/fund/novo-ventures)[**QED Investors** VC firm **6** rounds together](https://millionrounds.com/fund/qed-investors)

## Recently backed

The latest companies Invus put money into.

[**Matchpoint Therapeutics** $150M · Oct 2026](https://millionrounds.com/company/matchpoint-therapeutics)[**EliseAI** $350M · Sept 2026](https://millionrounds.com/company/eliseai)[**Precision Neuroscience** $250M · Sept 2026](https://millionrounds.com/company/precision-neuroscience)[**Tyra Biosciences** $400M · Sept 2026](https://millionrounds.com/company/tyra-biosciences)[**One Biosciences** $3.8M · Sept 2026](https://millionrounds.com/company/one-biosciences)[**Encoded Therapeutics** $275M · Sept 2026](https://millionrounds.com/company/encoded-therapeutics)

## Quick answers about Invus

### What does Invus invest in?

Invus invests most often at Venture and Series B (55% of the rounds on record), in sectors such as AI & Machine Learning, Artificial Intelligence & Machine Learning (AI/ML) and Asia Private Equity.

### How active is Invus?

148 investments on record, 26 of them in the last 12 months, and it led 4. The most recent was in Oct 2026.

### What has Invus invested in recently?

Its most recent investments on record: Matchpoint Therapeutics (Series B, Oct 2026), EliseAI (Growth, Sept 2026) and Precision Neuroscience (Growth, Sept 2026).

### How big are Invus's cheques?

The median round it joins is $81M.

### Does Invus lead rounds?

Sometimes: it led 4 of its 148 investments on record (3%).

### Where does Invus invest?

Most of the companies it backs are in the United States (78%) and France (11%).

### Is Invus investing now?

Yes: it is actively investing, with 26 investments in the last 12 months.

### Who does Invus invest alongside?

Most often RA Capital Management (15 rounds together), Fidelity (11 rounds together) and Janus Henderson Investors (10 rounds together).

## Raising now?

Find the investors who back rounds like yours, and keep every conversation on one fundraising board.

Find similar investorsOpen your CRM

Built from the rounds we watched, its filings and its own website, refreshed every night. [How we count](https://millionrounds.com/methodology) · [Report a correction](https://millionrounds.com/corrections?slug=invus) · [Is this your firm? Claim it](https://millionrounds.com/claim?org=invus)